Aspirin Use in Secondary Prevention for Patients with History of MI and LBBB

Benefits of Aspirin in Secondary Prevention

The American Heart Association recommends aspirin as Class I (Level of Evidence: A) therapy for secondary prevention in patients with prior MI, regardless of the presence of LBBB 1, 2
The European Society of Cardiology strongly recommends aspirin for secondary prevention (Class I, Level A) in the chronic phase (>12 months) after myocardial infarction 3, 4
Low-dose aspirin (75-100 mg daily) is specifically recommended in patients with a previous MI or revascularization by the European Society of Cardiology 5
Aspirin therapy administered within the first 24 hours after acute STEMI results in a 23% relative risk reduction in 5-week vascular mortality, according to the American College of Cardiology 6

Meta-analyses have confirmed the benefits of long-term aspirin therapy in patients at high risk of occlusive vascular events, including those with prior MI, as reported by the American Heart Association 7, 6
A meta-analysis of 16 secondary prevention trials (n=17,000 patients) demonstrated that aspirin allocation was associated with a 1.5% significantly lower risk of serious vascular events per year, according to the American College of Cardiology 7, 6

Following an initial loading dose of 162 to 325 mg of non-enteric-coated aspirin, an 81-mg daily dose is preferred to minimize bleeding risk, as recommended by the American Heart Association 7, 6

The presence of LBBB alone does not contraindicate aspirin use for secondary prevention of IHD, according to the American College of Cardiology 8, 9
LBBB is not listed among the contraindications or exceptions for aspirin therapy in any of the major guidelines, including those from the American Heart Association and the European Society of Cardiology 7, 6, 1

The European Society of Cardiology recommends clopidogrel 75 mg daily as a safe and effective alternative in patients with aspirin intolerance (Class I, Level A) 5
The CAPRIE trial showed a slight superiority of clopidogrel over aspirin; the rate of serious vascular events was 5.32% per year with clopidogrel vs. 5.83% with aspirin, as reported by the European Society of Cardiology 3, 4

The American College of Cardiology recommends aspirin should be continued indefinitely in patients recovering from NSTEMI as a Class I recommendation (Level of Evidence: A) 10, 11
For patients with unstable angina/NSTEMI treated medically without stenting, aspirin should be prescribed indefinitely 11
A maintenance dose of 81 mg daily is preferred to higher maintenance doses to minimize bleeding risk 10, 12, 13
Following an initial loading dose of 162 to 325 mg of non-enteric-coated aspirin during the acute event, an 81 mg daily dose is recommended for long-term therapy 14
It is reasonable to use an aspirin maintenance dose of 81 mg per day in preference to higher maintenance doses in patients with NSTE-ACS treated either invasively or with coronary stent implantation (Class IIa, Level of Evidence: B) 10

The risk of bleeding can be mitigated by using the lowest effective dose (81 mg daily) 10, 12
Considering proton pump inhibitor use in patients with history of gastrointestinal bleeding or those requiring triple antithrombotic therapy 10

For a patient with NSTEMI history and no fall risk, aspirin 81 mg daily should be prescribed indefinitely 10, 11, 12
Aspirin should be part of a comprehensive secondary prevention strategy that includes management of other cardiovascular risk factors 10, 15

The European Society of Cardiology recommends low-dose aspirin (75-100 mg daily) for patients with established coronary artery disease, reducing myocardial infarction risk by approximately 23-34% 16, 17
Aspirin 75 mg daily reduced myocardial infarction and sudden death by 34% after a median follow-up of 50 months in patients with chronic stable angina 16
Aspirin 162.5 mg started within 24 hours of symptom onset reduced vascular death by 23% at 5 weeks in patients with acute myocardial infarction 16, 17
Non-fatal vascular events were reduced by 50% in the acute setting with aspirin therapy 16, 17
Both aspirin and ticlopidine reduced myocardial infarction and death by approximately 50% in controlled studies of patients with unstable angina 16

The European Society of Cardiology recommends a daily maintenance dose of 75-100 mg aspirin for long-term secondary prevention 17
A loading dose of 162-325 mg non-enteric-coated aspirin should be administered immediately during acute coronary syndromes to ensure rapid and complete platelet inhibition 17

Clopidogrel showed only 8.7% greater reduction in cardiovascular events compared to aspirin 325 mg in the general population, but demonstrated 23.8% greater benefit specifically in PAD patients 18
Adding clopidogrel to aspirin in acute coronary syndromes without ST-elevation produced an additional 20% reduction in cardiovascular death, non-fatal MI, or stroke compared to aspirin alone 16

Major bleeding risk increases approximately 1.4-1.5 fold with aspirin 75-325 mg daily, but this is offset by the 23-34% reduction in ischemic events 16, 18
The absolute benefits substantially outweigh bleeding risks in moderate-to-high risk CAD patients (≥3% annual cardiovascular event risk) 17
Aspirin should be continued indefinitely in all CAD patients without contraindications, with benefit persisting without attenuation over extended follow-up periods of 50+ months 16